| **Author, year** | **Study design1** | **Start year of enrollment / Length of followup** | **Location / Multicenter** | **Adherence reported / Adherence >80% in each study arm** | **Inclusion criteria** |
| --- | --- | --- | --- | --- | --- |
| Alemzadeh, 2002200 | Retrospective cohort | Start year: NRFollowup duration: NR | EuropeSingle center | NA | Pediatrics, CD only, other criteria |
| Beaugerie, 2009130 | Prospective cohort | Start year: 2004Median followup duration: 35 months | EuropeMulticenter | NA | Pediatrics, adults, IBD, other criteria |
| Candy, 199553 | RCT, parallel arms | Start year: NRDuration of assigned treatment: 12 weeks | AfricaSingle center | No | Pediatrics, adults, CD only, no previous surgery (extensive surgery for Crohn's disease), CDAI (>200), not pregnant, not nursing, other criteria |
| Cezard, 2009194 | RCT, parallel arms | Start year: 1991Duration of assigned treatment: 1 years | EuropeMulticenter | No | Pediatrics, CD only, HBI (>5), no use of 5-aminosalicylate acids, thiopurines, methotrexate, active disease, other criteria |
| Crombe, 2011226EPIMAD | Retrospective cohort | Start year: 1988Median followup duration: 32 months | EuropeMulticenter | NA | Pediatrics, CD only, previous use of infliximab, other criteria |
| de Vries, 2008227 | Other study design | Start year: 1999Median followup duration: 9 years | EuropeSingle center | NA | Pediatrics, adults, IBD, no use of infliximab |
| D'Haens, 200848 | RCT, parallel arms | Start year: 2001Duration of assigned treatment: 2 years | EuropeMulticenter | YesYes | Pediatrics, adults, CD only, CDAI (>200), no use of corticosteroids, antimetabolites, biological agents, active disease, not pregnant, no obstructive symptoms with strictures, no history of TB, no cancer, other criteria |
| Escher, 2004190 | RCT, parallel arms | Start year: 1998Duration of assigned treatment: 12 weeks | EuropeMulticenter | No | Pediatrics, CD only, CDAI (>200), no use of corticosteroids, thiopurines, active disease, other criteria |
| Griffiths, 1993221 | RCT, crossover | Start year: 1988Duration of assigned treatment: 8 weeks | North AmericaSingle center | No | Pediatrics, CD only, HBI (>4), other criteria |
| Issenman, 1993196 | Prospective cohort | Start year: NR Mean followup duration: 2 years | North AmericaSingle center | NA | Pediatrics, CD only, males, active disease |
| Lees, 2009145 | Retrospective cohort | Start year: 1999Median followup duration: 2.4 years | EuropeMulticenter | NA | Pediatrics, adults, IBD, not pregnant, other criteria |
| Levine, 2002198 | Case-control study | Start year: NRFollowup duration: NR | IsraelMulticenter | NA | Pediatrics, CD only, PCDAI (12.5-40), no use of thiopurines, mild-moderate disease, other criteria |
| Levine, 2003191 | RCT, parallel arms | Start year: NRDuration of assigned treatment: 12 weeks | IsraelMulticenter | No | Pediatrics, CD only, no previous surgery (in past 6 weeks), PCDAI (12.5-40), no use of corticosteroids, thiopurines, active disease, other criteria |
| Malik, 2011229Royal Hospital Sick Children | Retrospective cohort | Start year: 2003 Mean followup duration: 12 months | EuropeSingle center | NA | Pediatrics, CD only, other criteria |
| Markowitz, 2000192 | RCT, parallel arms | Start year: NRDuration of assigned treatment: 18 months | USMulticenter | No | Pediatrics, CD only, moderate-severe disease, other criteria |
| Mate-Jimenez, 200052 | RCT, parallel arms | Start year: 1994Duration of assigned treatment: 26.5 months | EuropeSingle center | No | Pediatrics, adults, IBD, no previous surgery (extensive surgery), previous use of corticosteroids, not pregnant, not nursing, using adequate contraception, no abscess, other criteria |
| Present, 198060 | RCT, parallel arms, crossover | Start year: NRDuration of assigned treatment: 1 years | USSingle center | YesNo | Pediatrics, adults, CD only, active disease, other criteria |
| Rhodes, 197161 | RCT, crossover | Start year: NRDuration of assigned treatment: 2 months | Location: NRNumber of centers NR | YesNo | Pediatrics, adults, CD only |
| Russell, 2011236 | Prospective cohort | Start year: 2008Median followup duration: 0.8 years | EuropeMulticenter | NA | Pediatrics, IBD, other criteria |
| Saha, 1998197 | Prospective cohort | Start year: 1982Followup duration: NR | EuropeSingle center | NA | Pediatrics, IBD |
| Thayu, 2010199 | Case-control study | Start year: NR Mean followup duration: 43 months | USSingle center | NA | Pediatrics, CD only, no use of any medications affecting growth and development, other criteria |
| Thayu, 2010237CHOP | Prospective cohort | Start year: NR | USSingle center | NA | Pediatrics, CD only, other criteria |
| Thomson, 1990224 | RCT, parallel arms | Start year: NRDuration of assigned treatment: 12 months | North America, Europe, AfricaMulticenter | YesYes | Pediatrics, CD only, CDAI (<150), no use of azathioprine, metronidazole, no ostomy, no obstructive symptoms with strictures, other criteria |
| Van Assche, 200889 | RCT, parallel arms | Start year: 2004Duration of assigned treatment: 2 years | EuropeMulticenter | No | Pediatrics, adults, CD only, previous use of methotrexate, infliximab, immunosuppressives (azathioprine/6-MP or methotrexate), perianal fistulizing, not pregnant, not nursing, other criteria |

Abbreviations: 6-MP = 6-mercaptopurine; CD = Crohn’s disease; CDAI = Crohn’s Disease Activity Index; HBI = Harvey-Bradshaw Index; IBD = irritable bowel disease; PCDAI = Pediatric Crohn’s Disease Activity Index; NR = not reported; RCT = randomized controlled trial; TB = tuberculosis; US = United States